Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aztreonam

FDA-approved product (injectable, injection), marketed as Azactam, Azactam In Plastic Container, Aztreonam and 1 more.

Registered studies
50+
Lab records
165
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Aztreonam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Cystic fibrosis
  • Infection
  • Pneumonia
  • Pyelonephritis
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Monobactams
FDA pharmacologic class
Monobactam Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DF01; FDA class Monobactam Antibacterial

Repurposing investigation

Aztreonam is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli97.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 34 of 161 lab records
Open Aztreonam in ChEMBL Registered studies below
Show the latest 150 of 165 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aztreonam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

    NCT03329092 · start 2018-04-05

    Registered record
    Registry ID
    NCT03329092
    Conditions
    Complicated Intra-abdominal Infection; Hosptial Acquired Pneumonia; Ventilator Associated Pneumonia
    Interventions
    ATM-AVI; MTZ; MER; COL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-04-05
    Completion
    2023-02-23
    Enrolment
    422

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-abdominal Infection; Hosptial Acquired Pneumonia; Ventilator Associated Pneumonia
    InterventionATM-AVI; MTZ; MER; COL
    PhasePhase 3
    Registry statusCompleted

  • Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

    NCT03137173 · start 2018-02-19

    Registered record
    Registry ID
    NCT03137173
    Conditions
    Acute Bacterial Skin and Skin Structure Infections
    Interventions
    ceftobiprole medocaril; vancomycin+aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-02-19
    Completion
    2019-04-22
    Enrolment
    679

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Skin and Skin Structure Infections
    Interventionceftobiprole medocaril; vancomycin+aztreonam
    PhasePhase 3
    Registry statusCompleted

  • Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

    NCT03376529 · start 2017-11-10

    Registered record
    Registry ID
    NCT03376529
    Conditions
    Healthy Volunteers
    Interventions
    SPR741; Ceftazidime; Piperacillin/tazobactam; Aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-11-10
    Completion
    2017-12-20
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionSPR741; Ceftazidime; Piperacillin/tazobactam; Aztreonam
    PhasePhase 1
    Registry statusCompleted

  • Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

    NCT03078010 · start 2017-02-10

    Registered record
    Registry ID
    NCT03078010
    Conditions
    Intestinal Microbiome; Febrile Neutropenia
    Interventions
    Piperacillin-tazobactam; cefepime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-02-10
    Completion
    2027-02
    Enrolment
    347

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Microbiome; Febrile Neutropenia
    InterventionPiperacillin-tazobactam; cefepime
    PhasePhase 2
    Registry statusActive not recruiting

  • Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

    NCT02894684 · start 2017-01

    Registered record
    Registry ID
    NCT02894684
    Conditions
    Cystic Fibrosis; Infection; Pseudomonas
    Interventions
    Aztreonam; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01
    Completion
    2019-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Infection; Pseudomonas
    InterventionAztreonam; Standard Care
    PhasePhase 4
    Registry statusCompleted

  • Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae

    NCT02795949 · start 2016-10

    Registered record
    Registry ID
    NCT02795949
    Conditions
    Enterobacteriaceae Infections
    Interventions
    Antipseudomonal beta-lactam antibiotic; De-escalation(short-spectrum antibiotic)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-10
    Completion
    2020-01
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterobacteriaceae Infections
    InterventionAntipseudomonal beta-lactam antibiotic; De-escalation(short-spectrum antibiotic)
    PhasePhase 3
    Registry statusCompleted

  • Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)

    NCT02655419 · start 2016-05-19

    Registered record
    Registry ID
    NCT02655419
    Conditions
    Complicated Intra-Abdominal Infections, cIAIs
    Interventions
    ATM-AVI; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05-19
    Completion
    2017-10-26
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-Abdominal Infections, cIAIs
    InterventionATM-AVI; Metronidazole
    PhasePhase 2
    Registry statusCompleted

  • Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

    NCT02449031 · start 2015-05-05

    Registered record
    Registry ID
    NCT02449031
    Conditions
    Pseudomonas Aeruginosa in Cystic Fibrosis
    Interventions
    TOBI® PODHALER®; TOBI®; Bethkis®; Cayston®
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05-05
    Completion
    2021-12-31
    Enrolment
    409

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudomonas Aeruginosa in Cystic Fibrosis
    InterventionTOBI® PODHALER®; TOBI®; Bethkis®; Cayston®
    PhaseNot recorded
    Registry statusCompleted

  • A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection

    NCT02453789 · start 2015-02

    Registered record
    Registry ID
    NCT02453789
    Conditions
    Cystic Fibrosis; Burkholderia Infection
    Interventions
    Alginate oligosaccharide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02
    Completion
    2017-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Burkholderia Infection
    InterventionAlginate oligosaccharide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.

    NCT02202135 · start 2014-06

    Registered record
    Registry ID
    NCT02202135
    Conditions
    Complicated Skin and Soft Tissue Infection
    Interventions
    Ceftaroline fosamil; Vancomycin; Aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2014-06
    Completion
    2015-01
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Skin and Soft Tissue Infection
    InterventionCeftaroline fosamil; Vancomycin; Aztreonam
    PhasePhase 3
    Registry statusTerminated

  • Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

    NCT01984684 · start 2014-05

    Registered record
    Registry ID
    NCT01984684
    Conditions
    Skin and Subcutaneous Tissue Bacterial Infections; Skin Structures and Soft Tissue Infections
    Interventions
    delafloxacin; vancomycin; aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-05
    Completion
    2016-01
    Enrolment
    850

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin and Subcutaneous Tissue Bacterial Infections; Skin Structures and Soft Tissue Infections
    Interventiondelafloxacin; vancomycin; aztreonam
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis

    NCT07113587 · start 2014-04-08

    Registered record
    Registry ID
    NCT07113587
    Conditions
    Peritoneal Dialysis-associated Peritonitis; Peritoneal Dialysis (PD); Pharmacokinetics; Intravenous Administration; Intravenous; Meropenem; Intraperitoneal; Ampicillin; Aztreonam; Ciprofloxacin; Minimum Inhibitory Concentration (MIC)
    Interventions
    Application of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous ciprofloxacin in automated peritoneal dialysis patients without peritonitis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-04-08
    Completion
    2017-07-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeritoneal Dialysis-associated Peritonitis; Peritoneal Dialysis (PD); Pharmacokinetics; Intravenous Administration +7 more
    InterventionApplication of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous ciprofloxacin in automated peritoneal dialysis patients without peritonitis
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

    NCT01811732 · start 2013-04

    Registered record
    Registry ID
    NCT01811732
    Conditions
    Skin and Subcutaneous Tissue Bacterial Infections
    Interventions
    Delafloxacin; Vancomycin; Aztreonam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-04
    Completion
    2014-07
    Enrolment
    660

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin and Subcutaneous Tissue Bacterial Infections
    InterventionDelafloxacin; Vancomycin; Aztreonam; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

    NCT01641822 · start 2012-12

    Registered record
    Registry ID
    NCT01641822
    Conditions
    Cystic Fibrosis
    Interventions
    AZLI; Placebo to match AZLI; Tobramycin inhalation solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-12
    Completion
    2015-01
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionAZLI; Placebo to match AZLI; Tobramycin inhalation solution
    PhasePhase 3
    Registry statusCompleted

  • Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution

    NCT01736839 · start 2012-11

    Registered record
    Registry ID
    NCT01736839
    Conditions
    Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-11
    Completion
    2017-07-27
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted